Ceryvyn Therapeutics Ltd
OPT
Clasificación en acciones
#31877
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Precio por acción
$0.00846342
Última sincronización: 2026-07-27
Capitalización bursátil
$11.27M
Cambio (1 día)
0.00%
Cambio (1 año)
-99.75%
País
AU
Comercio Ceryvyn Therapeutics Ltd (OPT)
Categoría
Healthcare
EPS de Ceryvyn Therapeutics Ltd (OPT)
EPS a fecha de June 2025 TTM: $-1.84
Según los últimos informes financieros y el precio de las acciones de Ceryvyn Therapeutics Ltd, el EPS actual de la empresa (TTM) es $-1.84. Al final del año 2024, la empresa tenía un EPS de $-22.16 una disminución en comparación con al EPS de 2023, que fue de $-3.60.
Historial de EPS de Ceryvyn Therapeutics Ltd desde 2000 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $-1.84 | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | $-22.16 | 515.56% |
| 2023 | $-3.60 | 32.35% |
| 2022 | $-2.72 | 88.89% |
| 2021 | $-1.44 | 317.39% |
| 2020 | $-0.35 | -31.78% |
| 2019 | $-0.51 | 17.71% |
| 2018 | $-0.43 | 106.64% |
| 2017 | $-0.21 | -6.98% |
| 2016 | $-0.22 | 3.66% |
| 2015 | $-0.22 | -59.90% |
| 2014 | $-0.54 | -17.14% |
| 2013 | $-0.65 | -18.62% |
| 2012 | $-0.80 | -57.76% |
| 2011 | $-1.89 | 132.13% |
| 2010 | $-0.81 | -26.12% |
| 2009 | $-1.10 | 503.62% |
| 2008 | $-0.18 | -113.42% |
| 2007 | $1.36 | -307.90% |
| 2006 | $-0.65 | -130.68% |
| 2005 | $2.13 | 344.53% |
| 2004 | $0.48 | -270.17% |
| 2003 | $-0.28 | -13.83% |
| 2002 | $-0.33 | 328.31% |
| 2001 | $-0.08 | -179.65% |
| 2000 | $0.10 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| $17.32 | -1,041.30% |
US
|
|
| $-7.98 | 333.70% |
US
|
|
| $-5.29 | 187.50% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,607.61% |
NL
|
